Home Cart Sign in  
Chemical Structure| 73573-88-3 Chemical Structure| 73573-88-3

Structure of Mevastatin
CAS No.: 73573-88-3

Chemical Structure| 73573-88-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Mevastatin is the first discovered statin-class HMG-CoA reductase inhibitor used as a cholesterol-lowering agent isolated from Penicillium citinium.

Synonyms: Compactin; ML236B; Mevastatin, Compactin.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Mevastatin

CAS No. :73573-88-3
Formula : C23H34O5
M.W : 390.51
SMILES Code : CC[C@]([H])(C)C(O[C@]1(CCC=C(C=C[C@]([H])(C)[C@@]2(CC[C@]([H])(C[C@]([H])(C3)O)OC3=O)[H])[C@]12[H])[H])=O
Synonyms :
Compactin; ML236B; Mevastatin, Compactin.
MDL No. :MFCD05662341
InChI Key :AJLFOPYRIVGYMJ-INTXDZFKSA-N
Pubchem ID :64715

Safety of Mevastatin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
THP-1 macrophages 100 µg/ml 48 hours To study the effect of LDL modification on the expression of apoE, ABCA1, and ABCG1, results showed that modified LDL induced the expression of these genes. PMC14617
THP-1 macrophages 50 nM LG268, 2.0 µg/ml 22(S)-hydroxycholesterol, 2.0 µg/ml 20(S)-hydroxycholesterol, 2.0 µg/ml 22(R)-hydroxycholesterol 48 hours To study the regulation of apoE, ABCG1, and ABCA1 expression by LXR ligands, results showed that LXR ligands significantly induced the expression of these genes. PMC14617
rat cortical neurons 12.5 µM 12 hours Inhibits HMG-CoA reductase activity, thereby inhibiting cholesterol synthesis and neuronal activity PMC3628100

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice Lxr knockout mice oral 1.5 mg/kg Administered on days 5, 7, 9, and 12, totaling 4 doses To study the regulation of apoE expression by LXR ligands, results showed that LXR ligands induced apoE expression in adipose tissue but had minimal effect in the liver. PMC14617

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02441400 - Recruiting May 2019 Argentina ... More >> Fundacion Favaloro Recruiting Buenos Aires, Argentina Contact: Alejandro Nieponice, MD          Principal Investigator: Alejandro Nieponice, MD          Austria University Hospital Vienna Recruiting Vienna, Austria Contact: Sebastian Schoppmann, MD          Principal Investigator: Sebastian Schoppmann, MD          Denmark Aarhus University Hospital Recruiting Aarhus, Denmark Contact: Jan B Pedersen, MD          Principal Investigator: Jan B Pedersen, MD          Germany SANA Klinikum Lichtenberg Recruiting Berlin, Germany Contact: Dirk Federlein          Principal Investigator: Dirk Hartmann, MD          Evangelisches Krankenhaus Castrop-Rauxel Recruiting Castrop Rauxel, Germany Contact: Pravin Thattamparambil, MD          Principal Investigator: Pravin Thattamparambil, MD          St. Marienstift Krankenhaus Friesoythe Recruiting Friesoythe, Germany Contact: Ralf Weise, MD          Principal Investigator: Ralf Weise, MD          Hospital zum Heiligen Geist Fritzlar Recruiting Fritzlar, Germany Contact: Carsten Bismarck          Principal Investigator: Carsten Bismarck, MD          Klinikum Garmisch-Partenkirchen Recruiting Garmisch-Partenkirchen, Germany Contact: Holger Vogelsang          Principal Investigator: Holger Vogelsang, MD          Asklepios Klinik Altona Recruiting Hamburg, Germany Contact: Gero Puhl          Principal Investigator: Gero Puhl          KRH Klinikum Siloah Hannover Oststadt Recruiting Hannover, Germany Contact: Ahmed Madisch          Principal Investigator: Ahmed Madisch, MD          Evangelisches Krankenhaus Herne Recruiting Herne, Germany Contact: Matthias Kemen, MD          Principal Investigator: Matthias Kemen, MD          Klinikum Konstanz Recruiting Konstanz, Germany Contact: Ulrike Petzsche          Principal Investigator: Marcus Schuchmann, MD          Heilig Geist-Krankenhaus Köln Recruiting Köln, Germany Contact: Ernst Eypasch, MD          Principal Investigator: Ernst Eypasch, MD          Universitätsklinikum Magdeburg Recruiting Magdeburg, Germany Contact: Frank Benedix          Principal Investigator: Ulrike von Arnim          Universitätsmedizin Mannheim Recruiting Mannheim, Germany Contact: Mirko Otto          Principal Investigator: Kai Nowak, MD          Klinikum Memmingen Recruiting Memmingen, Germany Contact: Heinz Schlosser          Principal Investigator: Carsten Gutt, MD          Friedrich-Ebert-Krankenhaus Neumünster Recruiting Neumünster, Germany Contact: Andrea Pace          Principal Investigator: Andrea Pace, MD          Asklepios Schwalm-Eder Kliniken GmbH Recruiting Schwalmstadt, Germany Contact: Norbert Hesselbarth          Principal Investigator: Felix Meuschke, MD          Jung Stilling - Siegen Recruiting Siegen, Germany Contact: Daniela-Patricia Borkenstein          Principal Investigator: Joachim Labenz, MD          St. Marien-Krankenhaus Siegen Recruiting Siegen, Germany Contact: Dietmar Stephan, MD          Principal Investigator: Dietmar Stephan, MD          Ev. Krankenhaus Wesel GmbH Recruiting Wesel, Germany Contact: Vivianda Menke          Principal Investigator: Vivianda Menke, MD          Mexico Hospital San José Recruiting Monterrey, Mexico Contact: David Aguirre Mar, MD          Principal Investigator: David Aguirre Mar, MD          Netherlands Maastricht University Medical Center Recruiting Maastricht, Netherlands Contact: Nicole Bouvy, MD          Principal Investigator: Nicole Bouvy, MD          United Kingdom Spire Leicester Hospital Recruiting Leicester, United Kingdom Contact: Chris Sutton          Principal Investigator: Chris Sutton, MD          University Hospital Southampton Recruiting Southampton, United Kingdom Contact: Abrie Botha          Principal Investigator: Abrie Botha, MD Less <<
NCT01382511 Pachyonychia Congenita Not Applicable Unknown - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.56mL

0.51mL

0.26mL

12.80mL

2.56mL

1.28mL

25.61mL

5.12mL

2.56mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories